Recent data from the Phase 1/2 clinical trials of Tofersen, a gapmer designed to suppress SOD1 as a treatment for amyotrophic lateral sclerosis (ALS), reported pleocytosis within the CSF in 42% of the trial participants (Miller et al., 2020). Here, SOD1 is linked to amyotrophic lateral sclerosis.